Stephan Oertel

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

Ralf Ulrich Trappe, Stephan Oertel, Véronique Leblond et al. · The Lancet Oncology · 2011 · 386 citations

Medicine, Immunology, Oncology +9

Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD)

Stephan Oertel, Erik A.M. Verschuuren, Petra Reinke et al. · American Journal of Transplantation · 2005 · 259 citations

Life Sciences, Immunology, Pharmacotherapy +14

Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution

Sylvain Choquet, Stephan Oertel, Véronique Leblond et al. · Annals of Hematology · 2007 · 135 citations

Life Sciences, Hematology, Immunology +11

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Peter Hillmen, John G. Gribben, George Follows et al. · Journal of Clinical Oncology · 2014 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD

Kathrin Sebelin-Wulf, Tuan Duc Nguyen, Stephan Oertel et al. · Transplant Immunology · 2006 · 95 citations

Life Sciences, Immunology, Immunopathology +4